According to the latest State of Revenue survey of c-suite executives, pharma manufacturers are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Kyle Forcier
Advertisement
Kyle Forcier is the senior director of life sciences and product marketing for Model N.
Articles by Kyle Forcier
According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Advertisement
Latest Updated Articles
An Inside Look at Pharma Revenue ManagementPublished: March 8th 2023 | Updated: March 10th 2023
Advertisement
Advertisement
Trending on PharmExec
1
Real-World Data Brings New Insights to Natural History of Disease Studies
2
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
5